Chymostatin
Also known as: Chymostatin, Chymostatin A/B/C, Chymostatin mixture, N-[(S)-1-Carboxy-2-phenylethyl]-carbobenzyloxy-L-leucyl-L-leucyl-L-leucinal related, N‑acetyl‑L‑leucyl‑L‑phenylalanyl‑L‑phenylalaninal
Source Chymostatin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Chymostatin is a research‑grade peptide aldehyde that inhibits serine proteases such as chymase, cathepsin G, and other chymostatin‑sensitive enzymes. It is employed chiefly to study alternative, ACE‑independent pathways of angiotensin‑II formation and to protect therapeutic peptides from enzymatic degradation in vitro.
Mechanism of Action
Chymostatin acts as a covalent, reversible inhibitor of serine proteases by forming a hemi‑acetal with the catalytic serine residue in the enzyme active site. This blocks substrate access, preventing cleavage of peptide bonds. In cardiovascular tissue, it specifically inhibits the chymase‑type angiotensin‑II‑forming enzyme, distinguishing it from aprotinin‑sensitive kallikrein pathways.
What the Research Shows
Multiple hypertension‑focused reviews cite chymostatin‑sensitive, chymase‑type enzymes as contributors to local angiotensin‑II generation in heart and vessels, implicating them in remodeling and disease. Experimental work shows that chymostatin can block this pathway, although it does not account for all ACE‑independent angiotensin‑II production. In drug‑delivery research, chymostatin and related peptides are listed among inhibitors used to reduce proteolytic loss of orally administered peptides, and immobilisation of chymostatin on modified chitosan has been shown to protect proteins from pancreatic serine proteases in vitro.
Reported Benefits
As a selective tool, chymostatin helps delineate the role of chymase in tissue angiotensin‑II synthesis and assess the contribution of non‑ACE pathways to cardiovascular pathology. When co‑administered or immobilised in delivery matrices, it can markedly improve the stability and bioavailability of model peptide drugs in laboratory studies.
Limitations of the Evidence
Evidence is limited to in vitro assays, animal models, and mechanistic reviews; no clinical trials assess chymostatin itself. The inhibitor does not block all ACE‑independent angiotensin‑II formation, and its broad serine‑protease activity may affect multiple pathways, complicating interpretation. Safety, pharmacokinetics, and therapeutic efficacy remain uncharacterised.
Safety Considerations
Chymostatin has not been evaluated for human safety and is not approved for therapeutic use. Potential off‑target inhibition of essential serine proteases could cause unintended effects. Laboratory handling should follow standard biosafety procedures for protease inhibitors, and any in vivo use is restricted to controlled research settings.
How It Is Administered
Chymostatin is used exclusively in vitro, typically added to enzyme assays, tissue extracts, or incorporated into experimental delivery systems such as modified chitosan matrices. No oral, injectable, or other clinical formulations exist.
Routes of Administration
Goals & Uses
- Protease inhibition in biochemical assaysResearchHigh
- Protease inhibitor in cell lysis buffersResearch ToolHigh
- Inhibition of cathepsin G and chymaseResearch / BiochemistryModerate
- Study of apoptosis and autophagy pathwaysResearch / Cell BiologyModerate
- Inhibition of chymotrypsin-like serine proteasesResearch / BiochemistryHigh
- Inhibition of cysteine proteases (cathepsin B)Research / BiochemistryModerate
Contraindications
- Human or animal therapeutic administrationClinical UseHigh
Adverse Effects
- Cytotoxicity at high concentrationsIn Vitro ToxicityUncommon
- Non-specific protease inhibitionOff Target EffectCommon
Drug Interactions
No drug interactions recorded yet.
Population Constraints
- Not for human useGeneral PopulationAbsolute
Regulatory Status
- European UnionUnapprovedResearch reagent only
- United StatesUnapprovedResearch reagent only; sold under laboratory-use exemptions, not as a drug
- United KingdomUnapprovedResearch reagent only
Not approved for clinical use; supplied as a research reagent.
Evidence & Sources
- Journal ArticleModerateUrata H, Nishimura H, Ganten D1996-01-01T00:00:00.000000Z
- Journal ArticleModerateWeir MR, Dzau VJ1999-01-01T00:00:00.000000Z
- Journal ArticleModerateBernkop-Schnürch A1998-01-01T00:00:00.000000Z
- Journal ArticleModerateUrata H, Nishimura H, Ganten D1995-01-01T00:00:00.000000Z
- Journal ArticleModerateArakawa K1996-01-01T00:00:00.000000Z
- Journal ArticleModerateBernkop-Schnürch A, Kast CE2001-01-01T00:00:00.000000Z
Frequently Asked Questions
What does chymostatin inhibit?
It selectively blocks serine proteases that are sensitive to aldehyde‑based inhibitors, most notably the chymase‑type angiotensin‑II‑forming enzyme and related enzymes like cathepsin G.
Can chymostatin be used as a drug for hypertension?
No. All published data describe it only as a laboratory reagent; it has never been approved or tested in clinical trials for blood‑pressure treatment.
How does chymostatin improve oral peptide delivery?
When co‑administered or immobilised on polymers such as modified chitosan, it inhibits gastrointestinal serine proteases, reducing peptide degradation and thereby increasing the amount of intact drug that reaches the absorption site in experimental models.
Are there any known side effects in humans?
Human safety data are lacking. Because it can inhibit multiple serine proteases, potential adverse effects are theoretical and have not been documented.
Is chymostatin stable enough for use in experiments?
Yes. As a peptide aldehyde it remains active under typical in‑vitro assay conditions, but its stability can be affected by pH and temperature, requiring standard storage precautions.
What is Chymostatin?
Chymostatin is a research‑grade peptide aldehyde that inhibits serine proteases such as chymase, cathepsin G, and other chymostatin‑sensitive enzymes. It is employed chiefly to study alternative, ACE‑independent pathways of angiotensin‑II formation and to protect therapeutic peptides from enzymatic degradation in vitro.
What is Chymostatin used for?
Chymostatin is educationally associated with: Protease inhibition in biochemical assays, Protease inhibitor in cell lysis buffers, Inhibition of cathepsin G and chymase, Study of apoptosis and autophagy pathways, Inhibition of chymotrypsin-like serine proteases, Inhibition of cysteine proteases (cathepsin B). Educational only — not medical advice.
How is Chymostatin administered?
Recorded routes of administration: In Vitro, In Vitro (laboratory Use Only), Intraperitoneal, Intravenous.
What are the potential side effects of Chymostatin?
Reported adverse effects include: Cytotoxicity at high concentrations, Non-specific protease inhibition. This list is not exhaustive — consult a qualified clinician.
Who should avoid Chymostatin?
Recorded contraindications: Human or animal therapeutic administration. Consult a qualified clinician before use.